HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
STIM
Neuronetics, Inc.
STIM lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
STIM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
STIM's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
STIM PE Valuation
STIM has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
STIM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
STIM has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
STIM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.33 | +$0.50 |
| Q2 2026 | -$0.44 | +$0.70 |
| Q1 2026 | -$0.54 | +$0.78 |
| Q4 2025 | -$0.59 | +$0.79 |
| Q3 2025 | -$0.83 | +$0.38 |
| Q2 2025 | -$1.14 | -$0.04 |
| Q1 2025 | -$1.32 | -$0.38 |
| Q4 2024 | -$1.38 | -$0.33 |
STIM has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over STIM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
STIM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42M | +13% |
| Q2 2026 | $41.6M | +9.1% |
| Q1 2026 | $34.5M | +7.8% |
| Q4 2025 | $41.8M | +86% |
| Q3 2025 | $37.3M | +101% |
| Q2 2025 | $38.1M | +132% |
| Q1 2025 | $32M | +84% |
| Q4 2024 | $22.5M | +11% |
STIM's revenue has grown year over year for nine quarters in a row: $42M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.3% | +21 points |
| Q2 2026 | -3.6% | +18 points |
| Q1 2026 | -26% | +8.3 points |
| Q4 2025 | -12% | +39 points |
| Q3 2025 | -20% | +22 points |
| Q2 2025 | -21% | +31 points |
| Q1 2025 | -34% | +4.9 points |
| Q4 2024 | -51% | -29 points |
STIM has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over STIM on cash generation, producing positive trailing cash flow while its opponent burns cash.
STIM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $768K | +$1.7M |
| Q2 2026 | -$1.4M | +$2.3M |
| Q1 2026 | -$9.6M | +$7.6M |
| Q4 2025 | $692K | +$9.4M |
| Q3 2025 | -$899K | +$4.9M |
| Q2 2025 | -$3.8M | +$1.8M |
| Q1 2025 | -$17.2M | -$4.8M |
| Q4 2024 | -$8.7M | -793% |
STIM has burned cash in almost every quarter: −$10M over the past year, against −$31M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over STIM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
STIM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.3% | +3.9M shares |
| 1 year | +14% | +9.7M shares |
| 3 years | +169% | +48.4M shares |
| 5 years | +197% | +51.1M shares |
| Available history | +313% | +58.4M shares |
STIM has 77M diluted shares, up 14% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
STIM Net Leverage
STIM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
STIM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.4 | Neutral |
| Stochastic | 17.8 | Oversold |
STIM's weekly RSI is 39 (neutral) and its Stochastic is 18 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
STIM PE vs Healthcare Sector
STIM has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
STIM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.11 | 32% below |
| 20 week MA | $2.29 | 38% below |
| 50 week MA | $1.82 | 21% below |
| 100 week MA | $2.57 | 44% below |
| 200 week MA | $2.47 | 42% below |
STIM is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
STIM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.50 | $10.7 | +137% |
| 2021 | $10.7 | $4.60 | -57% |
| 2022 | $4.60 | $5.97 | +30% |
| 2023 | $5.97 | $2.90 | -51% |
| 2024 | $2.90 | $1.48 | -49% |
| 2025 | $1.48 | $1.42 | -4.1% |
| 2026 YTD | $1.42 | $1.43 | +0.7% |
STIM has the edge over HIMS on returns for 2026, with the stronger performance.